Polypeptide structural motifs associated with cell signaling activity

Patent metadata

Field	Value
Publication number	US-9453214-B2
Application number	US-201414452914-A
Country	US
Kind code	B2
Filing date	Aug 6, 2014
Priority date	Feb 27, 2009
Publication date	Sep 27, 2016
Grant date	Sep 27, 2016

Abstract

Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing.

First claim

What is claimed:

1. A pharmaceutical composition comprising an isolated seryl-tRNA synthetase (SerRS) polypeptide that is at least about 90% pure and consists essentially of three antiparallel β-sheets flanked at each end by an α-helix, wherein the polypeptide comprises a contiguous fragment of a human SerRS polypeptide as defined by SEQ ID NO:6, or a sequence having at least 90% sequence identity to said contiguous fragment and wherein the SeRS polypeptide is about 60 to 200 amino acid residues and exhibits a cell signaling activity.

2. The pharmaceutical composition of claim 1 , wherein the polypeptide comprises at least two non-contiguous fragments of a human SerRS polypeptide, or sequences having at least 90% sequence identity to said non-contiguous fragments.

3. The pharmaceutical composition of claim 1 , wherein the SerRS polypeptide consists essentially of residues 325-410 of SEQ ID NO: 6 or an active fragment or variant thereof having at least 95% sequence identity to residues 325-410 of SEQ ID NO: 6.

4. The pharmaceutical composition of claim 1 , wherein the polypeptide has chemokine activity.

5. A method for modulating cell signaling comprising contacting a cell with an effective amount of a pharmaceutical composition of claim 1 .

6. The method of claim 5 , wherein the method is selected from a method of modulating chemokine activity, a method of modulating TNF-α secretion, a method of inducing TNF-α secretion, a method of modulating immune cell chemotaxis, and a method of inducing monocyte chemotaxis.

Assignees

• Atyr Pharma Inc

Inventors

• Greene Leslie Ann

Classifications

• G01N2500/10

  involving cells · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C12Y601/01021

  Histidine-tRNA ligase (6.1.1.21) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• Y10T436/143333

  Saccharide [e.g., DNA, etc.] · CPC title